INO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Inovio Pharmaceuticals Inc (INO) is not a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock is facing significant negative catalysts such as ongoing lawsuits, poor financial performance, and bearish technical indicators. Additionally, there are no strong trading signals or positive catalysts to support a buy recommendation.
The technical indicators for INO are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 29.631, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.546), but there is no clear upward momentum.
NULL identified.
Multiple class action lawsuits alleging misrepresentation and financial misstatements, a significant revenue drop to $0 in Q4 2025, and negative sentiment from recent news.
In Q4 2025, revenue dropped to $0 (-100% YoY), net income fell to $3.76 million (-119.42% YoY), and EPS dropped to $0.06 (-109.23% YoY). These metrics indicate severe financial underperformance.
No recent analyst ratings or price target changes available.
